SAN DIEGO, Calif. – February 17, 2010 – Pharmatek Laboratories, Inc. , a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has successfully met Drug Enforcement Agency (DEA) requirements to be registered for the development and manufacture of Schedule IV and V controlled substances.
“Based on the needs of our clients, Pharmatek has put significant systems in place for the handling, inventory, development and manufacture of controlled substances,” said Kevin Rosenthal, Director of Manufacturing. “Being registered by the DEA validates our facility design, security systems, and procedures for manufacturing, handling, storage and disposal meet the stringent requirements of the DEA.”
Controlled substances are designated as Schedule I-V according to their medical use, potential for abuse and safety or dependence liability. In order to research, manufacture or distribute a controlled substance, a person or entity must be audited and registered by the DEA.
“Our goal is to continue to strive to meet the needs of our existing and prospective clients by adding to our capabilities in pharmaceutical chemistry development and manufacturing, said Timothy Scott, President at Pharmatek. “As a client-centric organization, our success is predicated on our ability to serve our clients. We are happy to bring this additional capability to Pharmatek in order to serve that purpose.”Leave a reply →